| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Boundless Bio, Inc.$2.41
-0.1 (-3.98%)
D 25Pipeline Score Richly Valued Biotech · Commercial
Market Cap
32.35 M
EPS
-2.50
P/E Ratio
-
Value Trade
192.53 K
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
9.73 M
Operating CF
-14.97 M
Total Assets
140.97 M
Total Liabilities
54.59 M
Equity
86.38 M
D/E Ratio
12,345
-7.69 %
Week
-7.43 %
1 Month
23.08 %
3 Month
29.73 %
6 Month
-89.89 %
5 Year
-89.89 %
All Time
Cash Data
Cash Position
92.85 M
Monthly Burn
4.99 M
Runway
16.7 mo
Burn Trend
SEC Filing
May 8, 2026
Overview
Volume
402.94 K
52 Week Range
0.96 - 1.68
% held by Insiders
23.35 %
% held by Institutions
49.51 %
Enterprise Value
-12.21 M
Total Shares
22.37 M
Short %
0.15 %
Float Shares
14.05 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Boundless Bio, Inc.
83Total events
5Upcoming
14Tier-1 (high impact)
2024 – 2026Coverage
Upcoming catalysts 5
Event history 78
Jun 23, 2026
▼Equity OfferingCorporate
Concurrent $230 million private placement co-led by RTW Investments and RA Capital Management
Jun 2026
▲Partnership / LicenseSERP-01Corporate
Serapha licenses SERP-01 from YolTech Therapeutics for Greater China rights
Alpha-1 Antitrypsin Deficiencysource ↗
Jun 2026
▲Trial InitiationSERP-01Trial
YolTech has been enrolling AATD patients in an IIT in Renji Hospital, Shanghai
Alpha-1 Antitrypsin Deficiencysource ↗
Jun 2026
May 8, 2026
◆Enrollment UpdateBBI-940Trial
Enrollment ongoing in KOMODO-1 trial of BBI-940
ER+/HER2- breast cancer, TNBC-LARsource ↗
Apr 21, 2026
◆Poster PresentationBBI-940Presentation
Poster presentation at AACR 2026 on BBI-940 preclinical data
advanced or metastatic estrogen receptor-positive, HER2-negative (ER+/HER2-) breast cancer or triple-negative breast cancer of the luminal androgen receptor subtype (TNBC-LAR)source ↗
Apr 21, 2026
◆Oral PresentationBBI-940Presentation
Preclinical data for BBI-940 presented at AACR 2026
ER+/HER2- breast cancer, TNBC-LARsource ↗
Apr 17, 2026
▲Trial InitiationBBI-940Trial
First-in-human Phase 1 KOMODO-1 trial initiated
advanced or metastatic ER+/HER2- breast cancer and TNBC-LARsource ↗
Q2 2026
◆Runway Guidance UpdateCorporate
Cash position expected to fund operations into second half of 2026
Drug Pipeline Intelligence
D25
Pipeline Score $1M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.1x
rNPV / MCap Top 25%
Micro Cap (rank 684 of 911)
Percentile RankBoundless Bio, Inc. faces pipeline headwinds (25/100), with $28M risk-adjusted pipeline value, led by BBI-940 in Breast Cancer (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BBI-940 Small molecule | Breast Cancer | Phase 1 | NCT07408089 | 5% | $28M | RECRUITING | 96 | VERY_FAST | D (32) | May 31, 2029 | ELEVATED_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BOLD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BOLD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BOLD▲ +85.7%on this news
Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement
Boundless Bio and Serapha Bio have announced a merger agreement, with Serapha Bio set to lead the combined company. The merger is supported by a $230 million private placement aimed at advancing Serapha's SERP-01 therapy for Alpha-1 Antitrypsin Deficiency. The transaction is expected to close in Q4 2026, pending stockholder approval and other conditions.
Read more →BOLD▼ -5.9%on this news
Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights
Boundless Bio reported its financial results for Q1 2026, highlighting ongoing enrollment in the KOMODO-1 trial for BBI-940, a novel kinesin degrader. The company has a strong cash position of $93 million, expected to fund operations through mid-2028. Recent data presented at the AACR Annual Meeting supports BBI-940's therapeutic potential in treating ecDNA+ cancers. However, the company reported a net loss of $13.6 million for the quarter.
Read more →BOLDBoundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
Boundless Bio presented promising preclinical data for BBI-940, an oral kinesin degrader, at the 2026 AACR Annual Meeting. The data supports its use in treating advanced or metastatic breast cancers, particularly those with extrachromosomal DNA. The ongoing Phase 1 KOMODO-1 trial aims to evaluate its safety and efficacy in patients with specific breast cancer subtypes.
Read more →BOLDBoundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026
Boundless Bio has announced a poster presentation for its oral Kinesin degrader program at the AACR Annual Meeting 2026. The presentation will detail the development of BBI-940, a selective Kinesin degrader aimed at treating advanced breast cancer types. This innovative approach targets extrachromosomal DNA, which is linked to oncogene amplification in cancer cells. The presentation is scheduled for April 21, 2026, in San Diego.
Read more →BOLDBoundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Boundless Bio reported its financial results for Q4 and full year 2025, highlighting the open enrollment for the KOMODO-1 trial of BBI-940, a novel Kinesin degrader for breast cancer. The company has $108 million in cash, expected to fund operations into 2028, and anticipates initial proof-of-concept data from the trial. However, it will cease enrollment in the POTENTIATE trial due to market considerations.
Read more →BOLDBoundless Bio to Participate in the Leerink Global Healthcare Conference
Boundless Bio, a clinical-stage oncology company, announced its participation in the Leerink Global Healthcare Conference. CEO Zachary Hornby will engage in a fireside chat on March 11 in Miami, Florida. The company focuses on developing therapies targeting extrachromosomal DNA to address oncogene amplified cancers.
Read more →BOLDBoundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Boundless Bio will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, with CEO Zachary Hornby leading a fireside chat. The event is scheduled for February 12 in New York. Boundless Bio focuses on developing therapies targeting extrachromosomal DNA to treat oncogene amplified cancers, addressing significant unmet medical needs.
Read more →BOLDBoundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway
Boundless Bio has received FDA acceptance for its IND application for BBI-940, a novel Kinesin degrader aimed at treating metastatic breast cancer. The first-in-human trial, KOMODO-1, is set to begin in the first half of 2026. The company has also decided to discontinue the POTENTIATE trial to focus on programs with greater potential. Additionally, Boundless Bio's financial strategy extends its operational runway into 2028.
Read more →BOLDBoundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference
Boundless Bio will participate in the Piper Sandler 37th Annual Healthcare Conference, with CEO Zachary Hornby scheduled for a fireside chat on December 3. The company is focused on developing therapies targeting extrachromosomal DNA in cancer treatment. Their ongoing clinical trials include innovative compounds aimed at oncogene amplified tumors.
Read more →BOLDBoundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights
Boundless Bio reported its third quarter 2025 financial results, highlighting ongoing enrollment in the POTENTIATE trial for BBI-355 and BBI-825. The company is also preparing for a first-in-human trial of BBI-940, expected to start in the first half of 2026. With $118 million in cash, Boundless Bio anticipates funding its operations through 2028, aiming for significant clinical readouts.
Read more →BOLDBoundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Boundless Bio has announced a poster presentation at the 2025 AACR-NCI-EORTC International Conference. The presentation will showcase their research on the synergistic effects of BBI-825 and BBI-355 in targeting oncogene amplified cancers. This event highlights the company's commitment to addressing unmet needs in cancer therapeutics.
Read more →BOLDBoundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights BBI-355 and BBI-825 combination arm of the POTENTIATE trial is now open for enrollment BBI-940 is on track for submission of an investig
Boundless Bio released its financial results and business highlights for Q2 2025, marking significant advancements in their oncology programs. The combination arm of the POTENTIATE trial for BBI-355 and BBI-825 is now open for enrollment, and the IND application for BBI-940 is on schedule for submission in early 2026. The company has a solid cash reserve of $127 million, expected to fund operations through early 2028. Executives express confidence in the scientific rationale behind their therapies aimed at oncogene-amplified cancers.
Read more →BOLDBoundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Boundless Bio will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, with CEO Zachary Hornby leading a fireside chat. The event is set for June 9 in Miami, FL, and will be accessible via a webcast. The company focuses on developing therapies targeting extrachromosomal DNA to treat oncogene amplified cancers.
Read more →BOLD▼ -15.6%on this news· ran to -29% by day 3
Boundless Bio Announces Portfolio Prioritization and Runway Extension
Boundless Bio has announced a strategic portfolio prioritization focusing on the combination therapy of BBI-355 and BBI-825, alongside the new candidate BBI-940. The company has extended its operational runway into the first half of 2028, allowing for anticipated proof-of-concept clinical readouts. However, it has discontinued certain clinical trials due to safety concerns.
Read more →BOLDBoundless Bio Reports First Quarter 2025 Financial Results and Business Highlights Initial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated
Boundless Bio reported its first-quarter financial results for 2025, highlighting a robust cash position of $138 million, projected to support operations into 2027. The company is optimistic about the upcoming proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial, anticipated in late 2025, and the nomination of a development candidate for its Kinesin program by mid-2025. Despite a slight increase in net loss and administrative expenses compared to the prior year, Boundless remains committed to developing therapies for oncogene-amplified cancers.
Read more →BOLD▼ -7.4%on this news· ran to -26% by day 3
Boundless Bio to Participate in the Needham Virtual Healthcare Conference
Boundless Bio will participate in the Needham Virtual Healthcare Conference on April 10, 2025. CEO Zachary Hornby is scheduled to present, highlighting the company's focus on extrachromosomal DNA in cancer therapies. The session will be available live and archived on their website, showcasing their innovative approach in oncology.
Read more →BOLDBoundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights BBI-355 Phase 1/2 POTENTIATE trial ongoing in patients with oncogene amplified cancers, with initial proof of concept data
Boundless Bio has reported its fourth quarter and full year 2024 financial results, highlighting the ongoing Phase 1/2 POTENTIATE trial for BBI-355 in oncogene amplified cancers. The company anticipates releasing initial proof-of-concept data for this drug in the second half of 2025. Additionally, the development of a novel Kinesin program is underway, with candidate nomination expected by mid-2025. Boundless Bio ended 2024 with a robust cash position of $152 million, projected to fund operations through 2027.
Read more →BOLDBoundless Bio to Participate in the Leerink Global Healthcare Conference
Boundless Bio, a clinical-stage oncology company, announced its participation in the Leerink Global Healthcare Conference. CEO Zachary Hornby will engage in a fireside chat on March 12, 2025, in Miami, FL. The session will be available via live and archived webcast. Boundless Bio focuses on therapies targeting extrachromosomal DNA for oncogene amplified cancers.
Read more →BOLDBoundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer
Boundless Bio has appointed Dr. Robert Doebele as Chief Medical Officer, a strategic move as the company progresses its BBI-355 Phase 1/2 trial. Dr. Doebele brings a wealth of experience in precision oncology, having previously co-founded Rain Oncology and led significant clinical developments. His expertise is expected to enhance Boundless Bio's mission to create innovative therapies for patients with oncogene amplified cancers.
Read more →BOLD▼ -12.7%on this news· ran to -27% by day 1
Boundless Bio Announces Pipeline and Leadership Updates Company elects not to advance BBI-825 into Part 2 portion of STARMAP clinical trial Third ecDTx program advancing, with plans for development candidate nomination b
Boundless Bio announced that it will not advance BBI-825 into the Part 2 portion of the STARMAP clinical trial due to insufficient dose-proportional exposure data and increased development costs. However, the company remains optimistic about its other projects, specifically BBI-355, for which initial data is expected in the second half of 2025, and a third ecDTx program, with a candidate nomination planned for mid-2025. Additionally, the company will undergo leadership changes, with the departure of top executives and an interim CMO appointed during the transition. Boundless has extended its operational runway into 2027 to support its ongoing research and development efforts.
Read more →BOLD▲ +8.9%on this news
Boundless Bio to Participate in the Piper Sandler Healthcare Conference
Boundless Bio (Nasdaq: BOLD) will participate in the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024. Zachary Hornby, the President and CEO, is scheduled for a fireside chat session to discuss the company's innovative approach to cancer therapy, particularly targeting extrachromosomal DNA (ecDNA) in oncogene amplified cancers. The company is advancing two ecDNA-directed therapies, BBI-355 and BBI-825, which are in Phase 1/2 clinical trials. Boundless Bio aims to address a significant unmet need in oncology by offering transformative therapeutic options for patients.
Read more →BOLDBoundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights Enrollment progressing in BBI-355 POTENTIATE and BBI-825 STARMAP clinical trials, with initial proof-of-concept data expected in the seco
Boundless Bio reported its financial results for Q3 2024, highlighting progress in enrollment for its BBI-355 and BBI-825 clinical trials. The company announced an initial proof-of-concept data expectation set for the second half of 2025. With a cash position of $167 million, Boundless Bio is well-capitalized to advance its programs focused on extrachromosomal DNA. The report also noted a net loss of $16.5 million for the quarter, an increase compared to the previous year.
Read more →BOLDBoundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference
Boundless Bio (Nasdaq: BOLD) has announced its participation in the 2024 Guggenheim Global Healthcare Conference, where CEO Zachary Hornby will engage in a fireside chat. The conference is scheduled for November 12, 2024, in Boston, MA. The company is focused on developing therapies targeting extrachromosomal DNA (ecDNA) to treat oncogene amplified cancers, with two therapies currently in Phase 1/2 trials. This participation emphasizes the company's commitment to addressing critical needs in oncology.
Read more →BOLDBoundless Bio Announces Departure of Chief Financial Officer
Boundless Bio announced the departure of its Chief Financial Officer, Jami Rubin, citing personal reasons. David Hinkle, the Senior Vice President of Finance and Controller, will take on the CFO's responsibilities temporarily. The company emphasized its strong position and ongoing clinical trials for therapies targeting oncogene amplified cancers, reflecting a positive outlook despite the leadership change.
Read more →BOLDBoundless Bio to Participate in the 2024 Cantor Global Healthcare Conference
Boundless Bio, a clinical-stage oncology company, has announced its participation in the upcoming 2024 Cantor Global Healthcare Conference. Key executives, Zachary Hornby and Jami Rubin, will engage in a fireside chat to discuss the company's innovative approaches to treating oncogene amplified cancers. Boundless Bio is particularly focused on extrachromosomal DNA (ecDNA) biology and is advancing multiple clinical trials, including those for its novel therapies BBI-355 and BBI-825. The event is scheduled for September 18, 2024, in New York City.
Read more →BOLD▼ -6.2%on this news
Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results BBI-355 POTENTIATE clinical trial ongoing with initiatives implemented to expedite enrollment in comb
Boundless Bio provided updates on its strategic priorities and reported its second-quarter financial results for 2024. The company is advancing its lead ecDTx candidate, BBI-355, while also managing slower-than-expected patient enrollment in its clinical trials. The ECHO diagnostic received IRB approval for use in the BBI-355 POTENTIATE trial, which demonstrates progress. To streamline operations, Boundless Bio is reducing its discovery initiatives and workforce to extend its financial runway into Q4 2026.
Read more →BOLD▲ +10.8%on this news
Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights BBI-355 Phase 1/2 POTENTIATE clinical trial ongoing; initiated targeted therapy combinations in patients with tumors with EGFR or FGFR o
Boundless Bio reported its first quarter financial results for 2024, highlighting continued progress in clinical trials for its ecDNA-targeted therapies. The POTENTIATE trial for BBI-355 and the STARMAP trial for BBI-825 both advanced with patient dosing. The company completed a successful $100 million IPO, ensuring capital to support its clinical research initiatives. However, it also faced increased operational costs and a notable net loss in the quarter.
Read more →Competitive Position
How BOLD ranks across every disease it competes inCompetitive Position is a premium feature
See how BOLD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial